Screener
Dianthus Therapeutics DNTH Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 29.3×+13.3× | 13.3×-1.9× | 17.3×-1.0× | 13.1×-23.3× | 16×-26.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $25.01+172% | —— | $14.46+46.5% | $8.46-19.2% | $9.18-36.8% | |
| Valuation | ||||||
| Market capitalization | $6.15B+838% | $1.77B+174% | $1.57B+67.1% | $583.38M-34.1% | $582.75M-24.3% | |
| Price / book | 5.1×+3.0× | 3.6×+1.8× | 2.9×+0.1× | 1.9×-0.5× | 1.8×-0.3× |
FAQ
- Where do Dianthus Therapeutics's ratios come from?
- Every ratio is computed from Dianthus Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.